Fruquintinib
Non-Small Cell Lung Carcinoma
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Immunitas Therapeutics
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05565417CT.gov Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | — | Active Not Recruiting | — | — | — |
NCT04956146CT.gov Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03976856CT.gov Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | — | Unknown | — | — | — |
NCT02976116CT.gov A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02691299CT.gov A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02590965CT.gov A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fruquintinib (this asset) | Immunitas Therapeutics | P3 | BB · 66 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Fruquintinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastasis From Malignant Tumor Of Colon | — | P3 | BBB · 72 |
| Colorectal Cancer | — | P4 | BB · 67 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fruquintinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fruquintinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →